Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 65%
filed 2026-06-15
The filing discloses a peer-reviewed publication of preclinical data for Telomir-Zn in a diabetes model, announced via press release on June 15, 2026. While this represents positive scientific validation for the company's lead clinical program (which has IND clearance), it does not fit cleanly into the standard 8-K event taxonomy. The disclosure is material to investors as it provides evidence supporting the mechanism of action and scientific foundation of the company's pipeline, but it is neither an earnings release, executive change, M&A activity, nor any other specifically enumerated event type.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-15
AIM ImmunoTech disclosed receipt of a letter from NYSE Regulation on June 12, 2026, confirming regained compliance with NYSE American continued listing standards. The filing explicitly references resolution of previously identified deficiencies under Section 1003(a)(i), (ii), and (iii) of the Company Guide and removal of the ".BC" (below compliance) indicator from the trading symbol. This is a material delisting-risk event because it documents the company's transition from noncompliance status back to compliance, directly addressing a prior listing threat.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-06-15
EX-99.1
The exhibit announces completion of a share buyback and cancellation of 6.6 million Class A Ordinary Shares (50% of a 13.2 million share Board-authorized mandate), with plans to remove up to 43.3 million additional shares representing ~36% of the public float. Share repurchases and cancellations are capital distributions that reduce issued share capital and accrete NAVPS for remaining shareholders, fitting the dividend_distribution category which encompasses "share-repurchase programs" and returns of capital.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Cuprina announced receipt of U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy. This is a significant regulatory milestone and product approval that enables commercial launch in the U.S. market. While not a discrete M&A, financing, or governance event, this regulatory clearance is a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's product portfolio and market opportunities, particularly as it positions Cuprina as the only company holding FDA clearance for both maggot species used in MDT.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-15
The filing discloses an "expanded relationship with VAST Data to power AI factories across Australia and Asia-Pacific" via press release under Item 7.01 (Regulation FD Disclosure). While the specific details are not provided in the 8-K body itself, the announcement of a material business partnership or strategic relationship with a named third party (VAST Data) for geographic expansion appears to be a significant corporate development. However, without access to the full press release text (Exhibit 99.1), the precise nature and materiality of this relationship—whether it constitutes a material contract, joint venture, or other arrangement—cannot be definitively determined, warranting classification as "other_material" rather than a more specific category.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-15
The filing discloses the appointment of Michael L. Hrynuik as Chief Financial Officer effective June 15, 2026, along with the concurrent resignation of prior principal accounting officer Scott M. Boruff. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO with detailed background and an employment agreement providing for base salary, bonus, and a 2,000,000 share restricted stock award. This is material to investors as CFO changes affect financial oversight and governance.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-15
EX-99.1
The exhibit announces the successful completion of the first tranche (50%) of InterCure's acquisition of Botanico Ltd., with issuance of 2,471,061 ordinary shares and contingent issuance of an additional 2,470,073 shares upon satisfaction of conditions. This is a material acquisition transaction that expands the company's portfolio with exclusive rights to U.S. cannabis genetics, premium brands, and advanced technologies, directly supporting the company's strategic vision.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-15
The filing discloses a change in the registrant's independent accountant under Item 4.01. On June 10, 2026, Omega Flex appointed PKF O'Connor Davies LLP as its new independent registered public accounting firm and dismissed RSM US LLP, which had served as the prior auditor. The filing confirms no adverse opinions, disagreements, or reportable events were associated with RSM's tenure, indicating a routine auditor transition following a competitive RFP process.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-15
The filing discloses a third drawdown of $30,000 under a sponsor promissory note on June 10, 2026, extending the Business Combination deadline from June 17 to July 17, 2026. This represents a material direct financial obligation and extension of a critical deadline for a SPAC, but does not fit cleanly into the standard taxonomy categories (not a covenant breach, as the note is unsecured and matures upon liquidation or closing; not a dilutive issuance, as it is a loan). The extension of the Termination Date is material to investors assessing the Company's timeline to complete its business combination.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-15
Item 5.02
The principal disclosed action is the appointment of Doug Cogan as President of the Company, effective June 9, 2026, while he continues as CEO. Although the filing also discloses a new employment agreement with compensation terms (base salary of $240,000, bonus eligibility, and a 2,500,000 share restricted stock award), the core event is the executive appointment. The appointment of a sitting CEO to the additional role of President is a material change in executive structure that would affect a reasonable investor's assessment of the company's governance and leadership.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 45%
filed 2026-06-15
EX-99.1
This exhibit is a notice and proxy statement for an Annual and Extraordinary General Meeting scheduled for July 23, 2026, containing six substantive proposals including auditor reappointment, board reappointment, external director reappointment with RSU grants, non-executive director RSU grants, CEO RSU grant, and approval of a Securities Exchange Agreement with VisionWave Holdings. However, the document is the *notice and solicitation* for the meeting, not the *results* of voting. The meeting has not yet occurred as of the filing date (June 15, 2026). While the VisionWave transaction (Proposal 6) is material M&A activity, this exhibit does not disclose voting results but rather seeks shareholder approval. The most accurate classification is the underlying material event—the VisionWave transaction—which should be classified as `ma_activity`, but the exhibit itself is a governance/voting solicitation document that does not fit cleanly into the taxonomy as presented.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-15
Roma Green Finance entered into an At the Market Offering Agreement on June 15, 2026, authorizing the sale of up to US$200 million in Class A ordinary shares through H.C. Wainwright & Co. as sales agent. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, material to investors as it represents a significant potential dilution to existing shareholders and a material capital-raising activity.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-06-15
The 6-K discloses that Takayuki Nakano resigned as a member of the Board of Directors on May 7, 2026. The filing explicitly states the resignation was not due to disagreement with operations or policies, and provides an updated list of executive officers and directors following the departure. This is a clear executive departure event requiring disclosure under Item 5.02 equivalent standards for foreign private issuers.
View raw filing on EDGAR →
6-K
Exec departure
confidence 75%
filed 2026-06-15
The filing discloses the resignation of three key executives effective June 11, 2026: Mr. Wai Ho Chan (Director and Chairman), Mr. Sze Hon Johnson Chen (Director and Chief Executive Officer), and Ms. Ka Lee Lam (Independent Director). While the filing also announces appointments of replacements, the principal disclosed action is the departure of these senior officers, particularly the CEO and Chairman, which materially affects the company's leadership structure and would be material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-15
Item 2.02 discloses that on June 15, 2026, PURE Bioscience issued a press release announcing financial results for the fiscal third quarter ended April 30, 2026. The press release is attached as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02 of Form 8-K.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-15
The filing discloses termination of a material definitive agreement—the Amended Altanine Merger Agreement—effective June 12, 2026, pursuant to Item 1.02. The parties "mutually agreed that the merger is no longer in the best interests" and terminated the agreement in its entirety. This represents a material change of control transaction that will not proceed, which would significantly affect investor assessment of the company's strategic direction and financial prospects.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-06-15
The filing's primary disclosure is Item 5.07, which reports the results of Bunker Hill Mining's June 11, 2026 annual meeting of stockholders. The filing details voting outcomes for five proposals: ratification of auditors (MNP LLC), election of six directors, approval of amended RSU and stock option plans, and advisory vote on named executive officer compensation. While Item 5.02 discusses the compensation plan amendments themselves, the central event reported is the shareholder vote results, which is material to investors assessing governance and capital allocation decisions.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-15
The filing discloses a loan modification agreement extending the maturity date of a $8.5 million secured real estate loan from July 2, 2026 to July 2, 2027, with a $2.4 million payment ($1.5M principal paydown plus $0.9M in prepaid interest and fees). While this involves debt restructuring, it does not fit cleanly into covenant_breach (no violation alleged), ma_activity (no acquisition/disposition), or other specific categories. The extension of a material debt obligation's maturity date is material to investors assessing liquidity and financial obligations, warranting disclosure under Item 8.01 Other Events.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-15
The filing discloses results of HCW Biologics Inc.'s 2026 Annual Meeting of Stockholders held on June 15, 2026, with voting outcomes on five proposals: election of Class II directors, ratification of Crowe LLP as auditor, approval of a reverse stock split (1:5 to 1:20 range) to maintain Nasdaq listing, approval of warrant issuance under Nasdaq Rule 5635(d), and approval of warrant repricing. This is a classic Item 5.07 shareholder vote results disclosure, material because the reverse split and warrant approvals directly affect shareholder equity and listing status.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-15
The filing discloses a press release under Item 7.01 (Regulation FD Disclosure) titled "Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption." While the actual press release content is not provided in the extracted text, the title suggests material business developments regarding platform adoption and commercial traction. This does not fit neatly into earnings_release (no financial results mentioned), ma_activity, or other specific event types, making other_material the most appropriate classification.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-15
EX-99.1
Gold Royalty Corp. announces the acquisition of an additional 0.1875% NSR royalty interest in the REN project for US$6.25 million cash consideration, increasing its total interest to 1.6875% NSR and 3.5% Net Profit Interest. This is a material acquisition of a royalty interest in a development-stage project expected to produce 140,000 ounces of gold annually, representing a discrete M&A transaction that would affect a reasonable investor's assessment of the company's asset base and cash deployment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-15
The filing discloses two material events under Item 5.02 and Item 5.07. The primary substantive disclosure is the Compensation Committee's approval on June 11, 2026 of an increase to CEO Vininder Singh's annual base salary from $400,000 to $600,000 (a 50% increase) and modification of his target annual bonus to a maximum of 50% of base salary. While the filing also reports shareholder vote results (Item 5.07), the compensation arrangement is the more significant material event requiring disclosure, as it represents a substantial change to executive compensation that would affect investor assessment of the company's cost structure and executive incentives.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-15
The filing discloses entry into a material definitive collaboration agreement (Item 1.01) under which Vivos Therapeutics will hold at least 80% of a newly formed management services organization (AIM Florida, LLC) in partnership with South Palm Cardiovascular Associates. This represents a material acquisition of membership interests and formation of a controlled entity, which constitutes M&A activity. The agreement contemplates significant operational and financial integration in the sleep apnea services market.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-15
Item 8.01
Bandwidth Inc. announced a proposed private offering of $275 million in convertible senior notes pursuant to Rule 144A, which is a material unregistered equity issuance. Convertible notes are inherently dilutive to existing shareholders upon conversion, and a $275 million offering represents a significant capital raise that would materially affect investor assessment of the company's capital structure and equity dilution risk.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-15
Item 2.02
The filing discloses that Dave & Buster's Entertainment issued a press release on June 15, 2026 announcing "results its first quarter 2026 results," with the press release attached as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance information.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-15
Item 8.01
NextNav announced a redemption of all outstanding 5.00% Senior Secured Convertible Notes due 2028 at 100% of principal plus accrued interest, with a redemption date of June 25, 2026. This is a material debt management and capital structure event affecting the company's liquidity position and financial obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-15
Item 5.07
This is a classic Item 5.07 disclosure reporting the certified results of Sprinklr's annual meeting of stockholders held on June 11, 2026. The filing presents voting outcomes for three proposals: (1) election of Stephen M. Ward, Jr. as a Class II director, (2) advisory approval of named executive officer compensation, and (3) ratification of KPMG LLP as independent auditor. All three matters are material governance events that affect investor understanding of board composition, executive compensation oversight, and audit firm selection.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This is a material product launch in the oncology segment with 180-day generic drug exclusivity, targeting a market with approximately $253.8 million in annual sales for the branded equivalent. The disclosure is a strategic operational milestone—a new product commercialization—rather than a discrete financial event (earnings, debt, M&A) or governance matter, making it operational_other.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-15
Item 7.01
The filing discloses resolution of a material delisting risk. Northann Corp. received a non-compliance notice from NYSE American on December 8, 2025 for failing to meet continued listing standards under Section 1003(a)(i) of the Company Guide. The company subsequently regained compliance on June 10, 2026, after demonstrating compliance for two consecutive quarters, resulting in removal from the noncompliant issuers list. This is a material event affecting the registrant's listing status and investor confidence.
View raw filing on EDGAR →
8-K
Earnings release
confidence 75%
filed 2026-06-15
Item 8.01
The Company issued a press release on June 15, 2026 announcing Phase 2 clinical trial results for ELI-002 7P in pancreatic cancer and outlining a refined Phase 3 development strategy. While this is clinical trial data rather than financial earnings, it is a material disclosure of significant clinical progress that would affect investor assessment of the Company's pipeline and development trajectory. The attachment of a press release and conference call presentation indicates this is a formal material announcement comparable in disclosure significance to an earnings release.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-15
Item 2.01
Talen Energy completed a material acquisition under a Merger Agreement, with the acquired companies becoming wholly owned subsidiaries. The transaction involved approximately $2.55 billion in cash consideration plus 2.399998 million shares of stock, funded by senior unsecured notes issued in April 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-15
Item 2.03
Talen Energy entered into a Seventh Amendment to its Credit Agreement, which increased revolving facilities from $900 million to $1.35 billion and extended maturity. The amendment's effectiveness was conditioned on substantially concurrent consummation of the acquisition.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-15
Item 8.01
The filing discloses a board decision to maintain the dividend rate on SATA Stock at 13.00% per annum and declares specific daily cash dividends for July 2026. While dividend declarations are routine for established dividend-paying securities, the 13% annual rate and the explicit tax guidance stating the company has no accumulated or current earnings and profits—and does not expect to generate earnings in the foreseeable future—signals that these are return-of-capital distributions rather than earnings-based dividends. This tax characterization and the forward guidance about absent profitability would be material to investors assessing the sustainability and nature of the distribution stream.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-15
Item 1.01
Enhanced Group Inc. entered into a securities purchase agreement on June 14, 2026, to issue 12,853,468 shares of Class A common stock and accompanying warrants for approximately $50 million in gross proceeds. The private placement, which requires stockholder approval due to potential dilution exceeding 19.99% of outstanding shares, was announced via press release and includes anti-dilution adjustments for 24 months.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-15
Item 1.02
Enhanced Group Inc. terminated a material debt instrument (the Note) through repayment using proceeds from the securities purchase agreement closing expected June 17, 2026, thereby eliminating a financing obligation and materially affecting the registrant's capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 75%
filed 2026-06-15
Item 5.07
The controlling stockholder approved via written consent a material private placement involving dilutive issuances exceeding 19.99% of outstanding shares, securities to related parties, and securities to the CEO, materially affecting voting power and ownership structure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-15
Item 8.01
Strive announced a significant bitcoin purchase of 73 BTC at ~$63,646 per coin during June 8-14, 2026, along with updates to its treasury holdings including cash, bitcoin, and STRC Stock positions. While this reflects the company's stated bitcoin treasury strategy, the disclosure does not fit neatly into standard 8-K event categories (not M&A, not a restatement, not an impairment, not a covenant breach). The material bitcoin acquisition and updated asset position warrant disclosure as a material corporate event affecting investor assessment of the company's financial posture and strategy execution.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-15
Item 8.01
Context Therapeutics announced positive interim efficacy and safety results from a Phase 1 clinical trial for CTIM-76, a bispecific antibody candidate, disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-15
Item 5.02
Mari J. Baker, a director and Chair of the Executive Compensation and Development Committee, notified the Board on June 10, 2026 of her intent not to stand for reelection at the September 24, 2026 Annual Meeting, completing her 15-year tenure. This is a material departure of a senior board member with significant committee leadership responsibilities, affecting board composition and governance structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-15
Item 8.01
This Item 8.01 disclosure provides a comprehensive NAV update as of May 31, 2026, including detailed valuation methodologies, property portfolio metrics (55 properties, 95% leased, 30% levered), June 2026 distribution declarations, and disclosure of a recent acquisition (Junction One, £50.0 million / $66.7 million retail property in Liverpool acquired May 15, 2026). While NAV updates are routine for non-traded REITs, the combination of material portfolio information, distribution details, and acquisition disclosure makes this material to investors assessing the registrant's financial position and asset base. The event does not fit neatly into more specific categories (not earnings, not M&A alone, not compensation), warranting classification as other_material.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-15
Item 2.01
Allbirds completed the sale of its entire footwear business, including intellectual property, inventory, and customer lists, to Allbirds IP LLC for $40.7 million in cash on June 9, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-15
Item 8.01
Allbirds announced a special dividend to stockholders funded by proceeds from the asset sale, with a record date of June 25, 2026 and payment within 60 days.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-15
Item 5.02
The disclosure centers on amendments to Adam K. Bowen's compensatory and employment arrangements as Interim CFO, including modifications to base salary, bonus structure, discretionary cash awards ($100,000 initial plus conditional quarterly awards), and LTI equity vesting terms. While the filing is under Item 5.02, the substantive focus is on compensation modifications rather than a departure or appointment event, making exec_compensation the most precise classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-15
Item 5.07
This is a clear disclosure of shareholder voting results from Kodiak AI's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports final voting tallies for two proposals: election of two Class I directors (Don Burnette and Kristin Sverchek) and ratification of Deloitte & Touche LLP as independent auditor. This is a textbook Item 5.07 disclosure of shareholder vote results, which is material to investors as it confirms governance outcomes and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-15
Item 5.07
This is a clear disclosure of shareholder vote results from NewtekOne's Annual Meeting of Shareholders held on June 12, 2026. The filing reports voting outcomes for three proposals: election of two directors (Proposal I), ratification of RSM US LLP as independent auditors (Proposal II), and advisory approval of named executive officer compensation (Proposal III), with detailed vote tallies for each. This is a quintessential Item 5.07 disclosure and is material to investors as it reflects shareholder governance decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-15
Item 5.07
This is a clear disclosure of shareholder voting results from Alliance Laundry Holdings' June 11, 2026 annual meeting, covering four proposals: election of Class I directors, ratification of Ernst & Young LLP as independent auditor, advisory vote on compensation vote frequency, and advisory vote on named executive officer compensation. The filing presents final vote tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-15
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Zoom's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting results for three proposals: election of Class I directors (Eric S. Yuan and Lieut. Gen. H.R. McMaster), ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The detailed vote tallies (FOR, AGAINST, ABSTAIN, BROKER NON-VOTE) are the core disclosure required by Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-15
Item 8.01
Rhythm Pharmaceuticals disclosed interim Phase 2 trial data for setmelanotide in Prader-Willi syndrome and other obesity-related indications, along with multiple clinical data presentations at the Endocrine Society's Annual Meeting (ENDO 2026), including efficacy and safety results showing BMI reductions and improvements in hyperphagia. This material clinical development milestone affects investor assessment of the company's pipeline and commercial prospects but does not fit the standard 8-K event taxonomy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-15
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Verde Clean Fuels' 2026 Annual Meeting held on June 12, 2026. The filing reports voting outcomes for two proposals: (1) re-election of Jonathan Siegler as Class III director with 38,174,994 votes for and 337,358 withheld, and (2) ratification of Deloitte & Touche LLP as independent auditor with 40,205,518 votes for and 5,701 against. These are routine but material governance matters that affect board composition and audit oversight.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-15
Item 2.02
The filing discloses financial results for the fiscal quarter and year ended April 30, 2026 via a press release attached as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly and annual financial performance information.
View raw filing on EDGAR →